These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 9595973)

  • 21. Cerebrospinal fluid abnormalities in a phase III trial of Avonex (IFNbeta-1a) for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group.
    Rudick RA; Cookfair DL; Simonian NA; Ransohoff RM; Richert JR; Jacobs LD; Herndon RM; Salazar AM; Fischer JS; Granger CV; Goodkin DE; Simon JH; Bartoszak DM; Bourdette DN; Braiman J; Brownscheidle CM; Coats ME; Cohan SL; Dougherty DS; Kinkel RP; Mass MK; Munchsauer FE; O'Reilly K; Priore RL; Whitham RH
    J Neuroimmunol; 1999 Jan; 93(1-2):8-14. PubMed ID: 10378864
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A sensitive radioimmunoprecipitation assay for assessing the clinical relevance of antibodies to IFN beta.
    Lawrence N; Oger J; Aziz T; Palace J; Vincent A
    J Neurol Neurosurg Psychiatry; 2003 Sep; 74(9):1236-9. PubMed ID: 12933925
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Persistent neutralizing antibodies abolish the interferon beta bioavailability in MS patients.
    Bertolotto A; Gilli F; Sala A; Capobianco M; Malucchi S; Milano E; Melis F; Marnetto F; Lindberg RL; Bottero R; Di Sapio A; Giordana MT
    Neurology; 2003 Feb; 60(4):634-9. PubMed ID: 12601105
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Methylprednisolone does not restore biological response in multiple sclerosis patients with neutralizing antibodies against interferon-β.
    Hesse D; Frederiksen JL; Koch-Henriksen N; Schreiber K; Stenager E; Heltberg A; Ravnborg M; Bendtzen K; Sellebjerg F; Sorensen PS
    Eur J Neurol; 2009 Jan; 16(1):43-7. PubMed ID: 19087149
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A multicenter, open-label, phase II study of the immunogenicity and safety of a new prefilled syringe (liquid) formulation of Avonex in patients with multiple sclerosis.
    Phillips JT; Rice G; Frohman E; Vande Gaer L; Scott T; Haas J; Eggenberger E; Freedman MS; Stuart W; Cunha L; Jacobs L; Oger J; Arnold D; Murray TJ; DiBiase M; Jethwa V; Goelz S
    Clin Ther; 2004 Apr; 26(4):511-21. PubMed ID: 15189748
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differing immunogenic potentials of interferon beta preparations in multiple sclerosis patients.
    Gneiss C; Tripp P; Reichartseder F; Egg R; Ehling R; Lutterotti A; Khalil M; Kuenz B; Mayringer I; Reindl M; Berger T; Deisenhammer F
    Mult Scler; 2006 Dec; 12(6):731-7. PubMed ID: 17263000
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interferon-beta: the neutralizing antibody (NAb) titre predicts reversion to NAb negativity.
    Gneiss C; Reindl M; Lutterotti A; Ehling R; Egg R; Khalil M; Berger T; Deisenhammer F
    Mult Scler; 2004 Oct; 10(5):507-10. PubMed ID: 15471365
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neutralizing antibodies reduce the efficacy of betaIFN during treatment of multiple sclerosis.
    Malucchi S; Sala A; Gilli F; Bottero R; Di Sapio A; Capobianco M; Bertolotto A
    Neurology; 2004 Jun; 62(11):2031-7. PubMed ID: 15184610
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies.
    Deisenhammer F; Reindl M; Harvey J; Gasse T; Dilitz E; Berger T
    Neurology; 1999 Apr; 52(6):1239-43. PubMed ID: 10214750
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interferon β-1b-neutralizing antibodies 5 years after clinically isolated syndrome.
    Hartung HP; Freedman MS; Polman CH; Edan G; Kappos L; Miller DH; Montalbán X; Barkhof F; Petkau J; White R; Sahajpal V; Knappertz V; Beckmann K; Lanius V; Sandbrink R; Pohl C;
    Neurology; 2011 Aug; 77(9):835-43. PubMed ID: 21849647
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neutralizing and binding anti-interferon-beta (IFN-beta) antibodies. A comparison between IFN-beta-1a and IFN-beta-1b treatment in multiple sclerosis.
    Kivisäkk P; Alm GV; Fredrikson S; Link H
    Eur J Neurol; 2000 Jan; 7(1):27-34. PubMed ID: 10809912
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group.
    Neurology; 1996 Oct; 47(4):889-94. PubMed ID: 8857714
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis (INCOMIN Trial) II: analysis of MRI responses to treatment and correlation with Nab.
    Barbero P; Bergui M; Versino E; Ricci A; Zhong JJ; Ferrero B; Clerico M; Pipieri A; Verdun E; Giordano L; Durelli L;
    Mult Scler; 2006 Feb; 12(1):72-6. PubMed ID: 16459722
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interferon beta neutralizing antibodies in multiple sclerosis: neutralizing activity and cross-reactivity with three different preparations.
    Bertolotto A; Malucchi S; Milano E; Castello A; Capobianco M; Mutani R
    Immunopharmacology; 2000 Jul; 48(2):95-100. PubMed ID: 10936507
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacodynamics of interferon beta in multiple sclerosis patients with or without serum neutralizing antibodies.
    Scagnolari C; Duda P; Bagnato F; De Vito G; Alberelli A; Lavolpe V; Girardi E; Durastanti V; Trojano M; Kappos L; Antonelli G
    J Neurol; 2007 May; 254(5):597-604. PubMed ID: 17420930
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discordant effect of IFN-beta1a therapy on anti-IFN antibodies and thyroid disease development in patients with multiple sclerosis.
    Monzani F; Meucci G; Caraccio N; Saviozzi M; Casolaro A; Moscato G; Lombardo F; Mosti S; Scagnolari C; Bruschi F; Antonelli G; Ferrannini E; Murri L
    J Interferon Cytokine Res; 2002 Jul; 22(7):773-81. PubMed ID: 12184915
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Natural killer cells in relapsing-remitting MS: effect of treatment with interferon beta-1B.
    Kastrukoff LF; Morgan NG; Zecchini D; White R; Petkau AJ; Satoh J; Paty DW
    Neurology; 1999 Jan; 52(2):351-9. PubMed ID: 9932956
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon beta-1b.
    Rice GP; Paszner B; Oger J; Lesaux J; Paty D; Ebers G
    Neurology; 1999 Apr; 52(6):1277-9. PubMed ID: 10214759
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunogenicity and tolerability of an investigational formulation of interferon-beta1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosis.
    Giovannoni G; Barbarash O; Casset-Semanaz F; Jaber A; King J; Metz L; Pardo G; Simsarian J; Sørensen PS; Stubinski B;
    Clin Ther; 2007 Jun; 29(6):1128-45. PubMed ID: 17692727
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ELISA methods for the analysis of antibody responses induced in multiple sclerosis patients treated with recombinant interferon-beta.
    Brickelmaier M; Hochman PS; Baciu R; Chao B; Cuervo JH; Whitty A
    J Immunol Methods; 1999 Jul; 227(1-2):121-35. PubMed ID: 10485260
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.